Vestal Point Capital LP Has $17.36 Million Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Vestal Point Capital LP lifted its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 307.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,630,000 shares of the company's stock after purchasing an additional 1,230,000 shares during the period. Vestal Point Capital LP owned 6.95% of UroGen Pharma worth $17,360,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma in the 4th quarter valued at approximately $59,000. Lazard Asset Management LLC acquired a new position in shares of UroGen Pharma during the fourth quarter worth approximately $67,000. Aquatic Capital Management LLC bought a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $101,000. Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma in the fourth quarter worth $126,000. Finally, ProShare Advisors LLC bought a new position in UroGen Pharma in the fourth quarter worth $137,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Price Performance

Shares of URGN traded down $0.09 on Thursday, hitting $4.08. The company's stock had a trading volume of 3,960,813 shares, compared to its average volume of 662,678. The company has a market capitalization of $188.12 million, a PE ratio of -1.30 and a beta of 0.66. UroGen Pharma Ltd. has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The company has a 50 day moving average price of $10.32 and a 200 day moving average price of $10.78. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on URGN. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday. HC Wainwright reissued a "neutral" rating on shares of UroGen Pharma in a report on Thursday. Scotiabank assumed coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price for the company. Finally, Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.